The I. Postovsky Institute of Organic Synthesis has developed a new original drug «Silativit» (organosilicon glicerohydrogel) that exhibits high anti-inflammatory, regenerative and transcutaneous activity. The drug is intended for treating local inflammatory diseases of oral cavity: chronic generalized gingivitis; chronic periodontitis mild case heaviness; lichen ruber planus (exudative-hyperaemia form and erosive form); traumatic blennosis of oral cavity; and chronic recurrent aphtous stomatitis. when used in stomatology for treatment of inflammatory diseases, Silativit rapidly arrests the inflammatory processes and has proven high therapeutic effect.

  Silativit is featured with a number of advantageous characteristic:
• It is cost-effcient and readily producible;
• It is nontoxic, has no cumulative effects, and does not cause local and systemic allergic reactions;
• It contains silicon, which is an essential microelement stimulating proliferative and reparative processes in tissues;
• It is characterized by transcutaneous and transmucous activity;
• It facilitates epithelization processes;
• It shows wound healing activity and exerts an antiinflammatory action;
• It is not prone to microbial contamination; and
• It is compatible with antibacterial and other biologically active substances.
 Field of Application: Stomatology.